Common Drugs With Cardiovascular Risk: What You Need to Know

Franklin Schneider, MD, FACC, FASE
Introduction:

- Many common medications have potential cardiovascular side effects.
- These medications can be safely used, in the appropriate patients.
- Will review a number of medications recently in medical and popular press.
Good drugs go bad: not always, but usually

Good Drugs, Bad Doctors
Introduction:

Specific Agents:
- Proton Pump Inhibitors (and Clopidogrel)
- Azithromycin
- Pioglitazone (Actos)
- NSAIDs
- COX-2 Inhibitors

Format:
- Define Interaction Issue
- Prescribing Recommendations
Proton Pump Inhibitors (and Plavix)

- Plavix reduces major CV events compared with placebo or aspirin.
- Dual antiplatelet therapy with Plavix/ASA reduces major CV events in patient with ischemic heart disease.
- Prolonged dual antiplatelet therapy is standard of care in patients after DES.
Proton Pump Inhibitors (and Plavix)

- Antiplatelet agents increase risk of bleeding (prior GI bleeding, older age, use steroids/anticoagulants, or NSAIDs).
- PPIs reduce risk of upper GI bleeding compared with no therapy.
- However, potential interactions between PPIs and Plavix have emerged. A significant association between PPI use and Plavix has been inconsistently demonstrated.
- The proposed mechanism is PPI inhibition of the CYP450 2C19-mediated metabolic bioactivation of clopidogrel.
Plavix and PPIs: What to do?

- Empiric use of PPIs should be avoided in patients treated with Clopidogrel.
- PPIs should only be considered in high-risk patients (history of gastrointestinal bleeding or ulcers, and those receiving concomitant anticoagulant therapy). PPIs to use are dextansoprazole, lansoprazole, or pantoprazole.
- Also consider use of H2-receptor antagonists or antacids.
Azithromycin and (Sudden) Death

Azithromycin and the Risk of Cardiovascular Death

Wayne A. Ray, Ph.D., Katherine T. Murray, M.D., Kathi Hall, B.S., Patrick G. Arbogast, Ph.D., and C. Michael Stein, M.B., Ch.B.

NEJM 366:20 May 17, 2012
Azithromycin and \( \uparrow \) (Sudden) Death

- Other macrolide antibiotics are associated with QT prolongation and increased arrhythmias.
- Retrospective (1992-2006) analysis of Tennessee Medicaid patients who took Azithromycin. Comparison groups took Amoxicillin, Levaquin, Cipro, or no Rx.
- 10 day post-Rx filling observation (5d Rx drug)
- Large # of prescriptions:
  - Azithromycin 347,795
  - Amoxicillin 1,348,672
  - Ciprofloxacin 264,626
  - Levaquin 193,306
  - No Abx 1,391,180 (Propensity matched)
Azithromycin and ↑(Sudden) Death

- 2.88 × ↑ risk of sudden death
- 1.86 × ↑ risk death by any cause
- ↑ 47 deaths per million.
- Risk Factors: Diabetes, CAD, Valve disease, CHF, PAD, use of certain medications – Digoxin, ACE-I, β-blockers

<table>
<thead>
<tr>
<th>Drug</th>
<th>Deaths</th>
<th>Death Rate/million</th>
</tr>
</thead>
<tbody>
<tr>
<td>Azithromycin</td>
<td>29/22</td>
<td>85.2</td>
</tr>
<tr>
<td>Amoxicillin</td>
<td>42/29</td>
<td>24</td>
</tr>
<tr>
<td>No Antibiotic</td>
<td>41/33</td>
<td>24</td>
</tr>
</tbody>
</table>
What to do?

- Avoid indiscriminate use of antibiotics.
- Avoid Azithromycin in patients with established CV disease, especially cardiomyopathy/CAD/CHF.
- Avoid use in higher risk individuals
- Consider use of alternative antibiotic agents
Pioglitazone (Actos) and CHF

- Thiazolidinediones (TZDs) have been associated with increased fluid retention.
- Rezulin pulled from market due to liver toxicity.
- Actos remains but has been associated with CHF.
  - 1.7-2.1 fold increase CHF after 24 weeks Rx.
  - 2.1 fold increase in HF resulting in hospitalization/death
  - 4-6% patients develop peripheral edema.
  - Observational studies: Increased weight gain and fluid retention.
Pioglitazone (Actos) and CHF

- **Mechanisms:**
  - Renal Na\(^+\) retention – stimulation sodium reabsorption in collecting tubule.
  - ? Aldosterone mediated effect

- **Recommendations:**
  - ↓ EF, no CHF – low dose TZD to start
  - ↓ EF, Class I-II CHF - low dose TZD to start
  - Class III-IV CHF – Avoid TZD use
  - If fluid retention occurs, assess for CHF.
  - If fluid retention, no evidence CHF, consider stopping medication.
When Good Drugs Go Bad
NSAIDs/COX-2 and Cardiac Events

- NSAIDs/COX-2 commonly used to treat pain and inflammation.
- However, these may have several negative effects on the CV system:
  - Interference with ASA effects.
  - Increased CV risk/events
  - Exacerbation of heart failure.
  - Cause (worsening) HTN control
NSAIDs/COX-2 and Cardiac Events

- Use of NSAIDs with concomitant ASA may attenuate beneficial effects of ASA
  - Ibuprofen given 2 hours before/after ASA decreased platelet inhibition.
  - Similar effects after a single dose Naproxen.
  - NSAIDs compete for common COX-1 binding site.

- MD Health Study: 2.9x ↑ MI NSAIDs ≥ 60 days.
NSAIDs/COX-2 and Cardiac Events

- NSAIDs and COX-2 increase CV risk:
  - NSAIDs – Absolute risk low, ↑ with dose.
    - Low risk/CAD pts - MI/CVA Ibuprofen (2.26), Diclofenac (1.6), Naproxen (1.23).
    - Unclear in patient with RA & CAD
  - COX-2 – ↑ Risk which vary depending upon agent and dose:
    - ↑ risk celebrex 1.35, Vioxx 2.12, Naproxen 0.82.
    - No known ↑ risk in patients with arthritis.
    - Effect occurs shortly after starting drug.
NSAIDs/COX-2 and Cardiac Events

- CAD
  - NSAIDS: ↑ risk death, recurrent MI 1.5x (least Naproxen)
  - COX-2 – ↑ CV events, non-cardiac pts.: Vioxx (2.6x), Celebrex (1.4x)
  - COX-2 - ↑ risk in known CV disease w/ Celebrex (1.9) – Risk developed with 7d of treatment
NSAIDs/COX-2 and Cardiac Events

- Worsening CHF
  - NSAIDs:
    - ↑(re)hospitalization CHF Diclofenac (1.35), Ibuprofen (1.16)
    - ↑ death diclofenac (2.1), Ibuprofen (>1200 mg 1.31), Naproxen (>500 mg 1.22),
    - ↑ afterload from vasoconstriction – Can also occur with ASA>325 mg. Reverses ACE-I/ARB effect.
  - COX-2:
    - ↑ Rates hospitalization CHF – Vioxx 2.7x, Celebrex 1.4x
    - ↑ Mortality – Vioxx, Celebrex (1.7 – 2.1x).
    - ↑ Risk renal failure when given to CHF patients.
NSAIDs/COX-2 and Cardiac Events

- HTN
  - NSAID use associated with ↑ BP.
  - COX-2 can ↑ BP – Vioxx > Celebrex
NSAIDs/COX-2: What to do?

- Factor in CV risk prior to NSAID Rx.
- Avoid use S/P CABG.
- Stop NSAID/COX-2 in patients with MI, CHF.
- Use lowest dose for shortest time.
- Use in caution with HTN – may exacerbate HTN
- (ACRhuematology) Consider risk/benefits NSAIDs - Naproxen NSAID of choice.
Conclusions:

- Many common medications have potential cardiovascular side effects.
- These medications can be safely used, but with appropriate care.
Thank you